Fractional deposition from a jet nebulizer: How it differs from a metered dose inhaler

doi:10.1016/0007-0971(85)90069-5

British Journal of Diseases of the Chest

Volume 79, 1985, Pages 361-367

https://doi.org/10.1016/0007-0971(85)90069-5 Get rights and content

Abstract

The fractional deposition from an Inspiron ‘Mini-Neb’ jet nebulizer was assessed in six normal and two asthmatic subjects using technetium-99m-labelled milli-microspheres of human serum albumin suspended in saline. Sixty-six per cent of activity was retained in the apparatus tubing, 20% exhaled, 2% deposited in the mouth and 12% was retained in the lungs. The nebulizer fractional deposition therefore differs from the findings reported for a metered dose inhaler (Newman et al. 1981; Spiro et al. 1984), where 80–85% of particles leaving the cannister deposits in the mouth, and only 5–10% in the apparatus. The lung fraction from a nebulizer is, however, similar to the 9–11% from an MDI.

References (16)

P.B. Anderson et al.
Comparison of salbutamol given by intermittent positive-pressure breathing and pressure-packed aerosol in chronic asthma
Thorax
(1982)
T. Asmundsson et al.
Efficiency of nebulizers for depositing saline in human lung
Am. Rev. resp. Dis.
(1973)
M.M. Clay et al.
Factors influencing the size distribution of aerosols from jet nebulisers
Thorax
(1983)
G.K. Crompton
Illogical warnings on Ventolin inhalers
Br. med. J.
(1984)
M.J. Cushley et al.
Comparison of three techniques of inhalation on the airway response to terbutaline
Thorax
(1983)
J.S. Fleming
A technique for the absolute measurement of activity using a gamma camera and computer
Phys. Med. Biol.
(1979)
I.W.B. Grant
Asthma in New Zealand
Br. med. J.
(1983)
R.A. Lewis
Inhalation drugs in asthma management: state of the art, factors affecting delivery and clinical response to inhaled drugs

There are more references available in the full text version of this article.

Cited by (70)

Recent advancements on novel approaches of insulin delivery
2023, Medicine in Novel Technology and Devices
A large number of populations are living with diabetes, which is the most common endocrine disorder which is classified into Type-I and Type-II diabetes. Diabetes is one of the listed diseases specified in Section 3 of the Drug and Magic Remedies Act, 1954, where advertisement of drugs for certain diseases has been prohibited. It can be managed or controlled with proper diagnosis and treatment and by changing food habits. In addition to therapy with oral hypoglycemic agents, patients are also given subcutaneous insulin injections which is traditionally used in diabetes therapy. This multi-dose injectable therapy has relatively low patient compliance. To avoid the associated drawbacks with this therapy, several other delivery techniques, including oral, buccal, rectal, transdermal and pulmonary routes were investigated for effective insulin delivery. Several novel techniques along with novel devices are discussed in this review. The recent development in insulin delivery and products going through various phases of clinical trials are focused here. This review enumerates how the investigation, recent technology, and developments in research played a pivotal role in the treatment of diabetes in near future with alternative, safe, and efficient insulin delivery.
Monoclonal antibody therapies against SARS-CoV-2
2022, The Lancet Infectious Diseases
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent immune escape. We show how the omicron (B.1.1.529) variant of concern has reset treatment strategies so far, discuss future developments that could lead to improved outcomes, and report the intrinsic limitations of using mAbs as therapeutic agents.
Nebulization of siRNA for inhalation therapy based on a microfluidic surface acoustic wave platform
2022, Ultrasonics Sonochemistry
Citation Excerpt :
Despite their appeal, there is room for improvement in the technological design of nebulizers, which include jet nebulizers, ultrasonic nebulizers, and the vibrating mesh nebulizer. Portability remains an issue with jet nebulizers, which can also suffer from delivery inefficiency with reports of only ∼12% delivered dose reaching the lung [15,16]. Modern ultrasonic nebulizers have become more portable, but suffer from the susceptibility of macromolecular drugs to denature under the large cavitation [17–19] and hydrodynamic shear forces induced by the piezoelectric crystal-driven nebulization process [13,14].
The local delivery of therapeutic small interfering RNA or siRNA to the lungs has the potential to improve the prognosis for patients suffering debilitating lung diseases. Recent advances in materials science have been aimed at addressing delivery challenges including biodistribution, bioavailability and cell internalization, but an equally important challenge to overcome is the development of an inhalation device that can deliver the siRNA effectively to the lung, without degrading the therapeutic itself. Here, we report the nebulization of siRNA, either naked siRNA or complexed with polyethyleneimine (PEI) or a commercial transfection agent, using a miniaturizable acoustomicrofluidic nebulization device. The siRNA solution could be nebulised without significant degradation into an aerosol mist with tunable mean aerodynamic diameters of approximately 3 µm, which is appropriate for deep lung deposition via inhalation. The nebulized siRNA was tested for its stability, as well as its toxicity and gene silencing properties using the mammalian lung carcinoma cell line A549, which demonstrated that the gene silencing capability of siRNA is retained after nebulization. This highlights the potential application of the acoustomicrofluidic device for the delivery of efficacious siRNA via inhalation, either for systemic delivery via the alveolar epithelium or local therapeutic delivery to the lung.
Update efficacy of aerosol therapy with noninvasive ventilator approach (non-invasive ventilation and nasal high flow): Aerosol delivery via noninvasive ventilation
2020, Journal of Drug Delivery Science and Technology
Citation Excerpt :
Madney et al. investigated the difference between VMN; Aerogon Solo and JN, placed on the downstream position, in the delivery of inhaled salbutamol within a high flow system at a low flow rate of 5 L/min. Their findings showed that the total inhalable dose with VMN is about two-fold higher than that with JN in agreement with reported disadvantages of JN during NIV [26,162,163]. A recent in-vivo study compared the delivery of VMN versus JN within a high flow system at a low oxygen flow rate of 5 L/min (100% oxygen concentration) on COPD patients [154].
Aerosol delivery by nebulizers and pressurized metered-dose inhalers (pMDIs) attached through an adapter or spacer into a ventilation circuit during noninvasive mechanical ventilation (NIV) and high flow nasal cannula (HFNC) add great benefits in the management of obstructive lung disease patients. The inhaled medication, given during NIV and HFNC, offers better and quicker clinical effects than with unassisted breathing. Unfortunately, there is no specific recommendation or guidelines to guide therapists/clinicians in their decisions while delivering aerosols to ventilated patients which puts the patients at risk of receiving either a sub-therapeutic or toxic dose of their inhaled medications. This increases the urgency for the development of recommendations/guidelines by a trusted board/society for aerosol delivery to such critically ill patients. This review article could serve as a good guide in this field especially the methods used to quantify aerosol delivery during NIV or HFNC.
Size distribution of salbutamol/ipratropium aerosols produced by different nebulizers in the absence and presence of heat and humidification
2018, Pulmonary Pharmacology and Therapeutics
Citation Excerpt :
The extent of aerosol delivery is influenced by the nebulizer employed [10–13]. Previous studies have showed that 10–20% of the aerosolized drug was deposited in the lungs, while 80% remained in the throat (oropharynx), nebulizer, ventilator circuit, and ambient environment [14,15]. The use of different interfaces also affected aerosolized drug delivery; these include the aerosol mask [6], tracheal mask [8,16], T-piece [17], endotracheal tube [11,18,19], and tracheostomy tube [20].
Few studies have evaluated the size distribution of inhaled and exhaled aerosolized drugs, or the effect of heated humidification on particle size and lung deposition. The present study evaluated these aspects of bronchodilator (salbutamol/ipratropium) delivery using a lung model in the absence and presence of heat and humidification.
We positioned filters to collect and measure the initial drug, inhaled drug, and exhaled drug. Particle size distribution was evaluated using an 8-stage Marple personal cascade impactor with 0.2-μm polycarbonate filters.
A greater inhaled drug mass was delivered using a vibrating mesh nebulizer (VMN) than by using a small volume nebulizer (SVN), when heated humidifiers were not employed. When heated and humidified medical gas was used, there was no significant difference between the inhaled drug mass delivered by the VMN and that delivered by the SVN. A significantly greater mass of inhaled 1.55-μm drug particles was produced by the VMN than with the SVN, under heated and humidified conditions. However, the mass median aerodynamic diameters (MMADs) of the aerosolized drug produced by the SVN and VMN did not differ significantly under the same conditions.
The VMN produced more fine particles of salbutamol/ipratropium, and the drug particle size clearly increased in the presence of heat and humidification.
Protein stability in pulmonary drug delivery via nebulization
2015, Advanced Drug Delivery Reviews
Citation Excerpt :
A significant amount of medication is wasted since these devices have a residual “dead” volume of 0.5 to 1.5 mL and usually operate continuously also during exhalation phases. Thus while the respirable fraction of the generated aerosol is in a range of 30–70% [122], only 5–15% of the initial charge actually deposits in the lung [123–127]. This is a significant disadvantage considering the comparably high value of biopharmaceuticals.
Protein inhalation is a delivery route which offers high potential for direct local lung application of proteins. Liquid formulations are usually available in early stages of biopharmaceutical development and nebulizers are the device of choice for atomization avoiding additional process steps like drying and enabling fast progression to clinical trials. While some proteins were proven to remain stable throughout aerosolization e.g. DNase, many biopharmaceuticals are more susceptible towards the stresses encountered during nebulization. The main reason for protein instability is unfolding and aggregation at the air–liquid interface, a problem which is of particular challenge in the case of ultrasound and jet nebulizers due to recirculation of much of the generated droplets. Surfactants are an important formulation component to protect the sensitive biomolecules. A second important challenge is warming of ultrasound and vibrating mesh devices, which can be overcome by overfilling, precooled solutions or cooling of the reservoir. Ultimately, formulation development has to go hand in hand with device evaluation.

View all citing articles on Scopus

View full text

General articleFractional deposition from a jet nebulizer: How it differs from a metered dose inhaler

Abstract

Comparison of salbutamol given by intermittent positive-pressure breathing and pressure-packed aerosol in chronic asthma

Thorax

Efficiency of nebulizers for depositing saline in human lung

Am. Rev. resp. Dis.

Factors influencing the size distribution of aerosols from jet nebulisers

Thorax

Illogical warnings on Ventolin inhalers

Br. med. J.

Comparison of three techniques of inhalation on the airway response to terbutaline

Thorax

A technique for the absolute measurement of activity using a gamma camera and computer

Phys. Med. Biol.

Asthma in New Zealand

Br. med. J.

Inhalation drugs in asthma management: state of the art, factors affecting delivery and clinical response to inhaled drugs

General article
Fractional deposition from a jet nebulizer: How it differs from a metered dose inhaler